MacroGenics (MGNX)
(Real Time Quote from BATS)
$4.26 USD
-0.02 (-0.35%)
Updated Jul 10, 2024 03:22 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
MacroGenics (MGNX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.50 | $28.00 | $4.00 | 192.06% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for MacroGenics comes to $12.50. The forecasts range from a low of $4.00 to a high of $28.00. The average price target represents an increase of 192.06% from the last closing price of $4.28.
Analyst Price Targets (10)
Broker Rating
MacroGenics currently has an average brokerage recommendation (ABR) of 1.73 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.73 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, seven are Strong Buy, representing 63.64% of all recommendations. A month ago, Strong Buy represented 63.64%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.73 | 1.73 | 1.73 | 1.73 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/10/2024 | Cowen & Co. | Tara Bancroft | Strong Buy | Hold |
5/10/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Hold |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Hold |
4/26/2024 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
4/3/2024 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
3/11/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
3/11/2024 | H.C. Wainwright & Co. | Robert Burns | Hold | Hold |
3/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/4/2024 | BTIG | Kaveri Pohlman | Strong Buy | Strong Buy |
3/1/2024 | SVB Securities | Jonathan W Chang | Strong Buy | Strong Buy |
12/20/2023 | Not Identified | Not Identified | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.73 |
ABR (Last week) | 1.73 |
# of Recs in ABR | 11 |
Average Target Price | $12.50 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 170 of 252 |
Current Quarter EPS Est: | -0.75 |